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While investigating the ability of p38 MAPK to regu-
late cytarabine (Ara C)-dependent differentiation of
erythroleukemia K562 cells, we observed effects that
indicated that the imidazoline class of p38 MAPK inhib-
itors prevented nucleoside transport. Incubation of
K562 cells with SB203580, SB203580-iodo, or SB202474,
an analogue of SB203580 that does not inhibit p38 MAPK
activity, inhibited the uptake of [3H]Ara C or [3H]uri-
dine and the differentiation of K562 cells. Consistent
with the effects of these compounds on the nitrobenzyl-
thioinosine (NBMPR)-sensitive equilibrative nucleoside
transporter (ENT1), incubation with SB203580 or
SB203580-iodo eliminated the binding of [3H]NBMPR to
K562 cells or membranes isolated from human erythro-
cytes. Furthermore, using a uridine-dependent cell type
(G9c), we observed that SB203580 or SB203580-iodo effi-
ciently inhibited the salvage synthesis of pyrimidine
nucleotides in vivo. Thus these studies demonstrate that
the NBMPR-sensitive equilibrative nucleoside trans-
porters are novel and unexpected targets for the p38
MAPK inhibitors at concentrations typically used to in-
hibit protein kinases.
Nucleoside transporters are essential for the salvage path-
way synthesis of nucleic acids and the transport of a wide range
of nucleoside analogues used in the treatment of human neo-
plastic and viral diseases, including leukemia and AIDS (1, 2).
Most mammalian cells co-express several nucleoside trans-
porter isoforms at the plasma membrane that differ in their
cation-dependent, permeant selectivities and inhibitor sensi-
tivities and can generally be assigned to one of two major
classes designated as the equilibrative or concentrative trans-
porters (3). The Na-independent equilibrative nucleoside
transporters (ENTs)1 transport nucleosides by chemical gradi-
ents and can be further divided into equilibrative-sensitive (es)
and equilibrative-insensitive (ei) (encoded by ENT1 and ENT2
gene, respectively) based on sensitivity, or insensitivity, to the
high affinity antagonist nitrobenzylthioinosine (NBMPR) (3,
4). The es transporters are widely expressed, whereas ei trans-
porters are found as a minor component in intestine, hemato-
poietic cells, skeletal muscle, and cardiovascular tissue (3–5).
The MAPKs are a large family of enzymes responsible for
relaying cell surface signals to the nucleus and other intracel-
lular targets (6). Not surprisingly these enzymes are highly
desirable targets for pharmacological inhibitors of cell signal-
ing. SB203580 was identified as one of the first highly selective
inhibitors of the stress-activated p38 mitogen-activated protein
kinases (p38 MAPKs) and was shown to block the production of
tumor necrosis factor- and interleukin-1 release from lipopo-
lysaccharide-stimulated monocytes (7). Considerable evidence
now suggests that SB203580 exerts its anti-inflammatory ac-
tions by binding to the ATP binding site and inhibiting the
activity of p38 MAPK (7–9). SB203580 and related analogues
have also been shown to inhibit the production of interferon-,
interleukin-2, and tumor necrosis factor- by lymphocytes
stimulated with lipopolysaccharide, phorbol myristate acetate,
sorbitol, and anti-CD3 plus anti-CD28 monoclonal antibodies
(10–13). Since this initial discovery a wealth of studies has
contributed to the discovery and design of a series of pyrimi-
dine analogues as additional p38 MAPK inhibitors, some of
which are currently in clinical trials for rheumatoid arthritis
(14–16).
While investigating the involvement of p38 MAPK in the
regulation of erythroid cell differentiation, we observed effects
of SB203580 that were inconsistent with inhibition of this
kinase. Instead our results suggested that there were addi-
tional effects on the transport of nucleosides or nucleoside
analogues into K562 cells. In this report we describe evidence
for the equilibrative nucleoside transporters as additional tar-
gets for inhibition by the imidazoline class of p38 MAPK
inhibitors.
MATERIALS AND METHODS
Cell Cultures and Reagents—Human erythroleukemia K562 cells
and G9c cells were cultured as described earlier (17). Uridine (35–50
Ci/mmol) was purchased from ICN Biomedicals (Costa Mesa, CA).
[3H]NBMPR (22.5 Ci/mmol) and [5-3H]cytosine--D-arabinofuranoside
([5-3H]Ara C, 15–30 Ci/mmol) were from Moravek Biochemicals (Brea,
CA). Uridine, propidium, NBMPR, and Histopaque were obtained from
Sigma. SB202190, SB202474, SB203580, SB203580-iodo, and
SB220025 were purchased from Calbiochem-Novabiochem.
Measurement of Erythroid Differentiation of K562 Cells by Benzidine
Staining—Erythroid differentiation was determined by measuring he-
moglobin production by benzidine staining (17). Benzidine dihydrochlo-
ride (2 mg/ml) was prepared in 0.5 M (3%) acetic acid, and H2O2 (1%)
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was added immediately before use. The cell suspensions were mixed
with the benzidine solution in a 1:1 ratio and counted in a hemocytom-
eter after 5 min. Blue cells were considered positive for hemoglobin, and
at least 1000 cells were counted per sample.
Uptake Assays of [3H]Ara C by K562 Cells—Uptake assays of [3H]Ara
C was conducted in RPMI 1640 medium at 37 °C. 5  105 K562 cells/
sample were washed once with RPMI 1640 medium and then resus-
pended in 400 l of RPMI 1640 medium. After preincubation with SB
analogues or control Me2SO for 15 min, an equal volume of RPMI 1640
medium containing 3H-labeled Ara C (100 nM) plus inhibitors or control
Me2SO was added for 30 min. Uptake of
3H-labeled Ara C was stopped
by five rapid washes with ice-cold RPMI 1640 medium containing 200
M unlabeled competing Ara C. Nonspecific binding was measured in
the presence of 200 M unlabeled Ara C. The cell pellets were lysed in
10% SDS before quantification of radioactivity.
Uptake Assays of [3H]Uridine—Uridine uptake assays were con-
ducted as described previously (18) at room temperature in sodium-
containing buffer (20 mM Tris/HCl, 3 mM K2HPO4, 1 mM MgCl26H2O, 2
mM CaCl2, 5 mM glucose, and 130 mM NaCl, pH 7.4) or sodium-free
transport buffer (20 mM Tris/HCl, 3 mM K2HPO4, 1 mM MgCl26H2O, 2
mM CaCl2, 5 mM glucose, and 130 mM N-methyl-D-glucamine/HCl, pH
7.4). 5  105 K562 cells/sample or G9c cells were washed once with
transport buffer and then resuspended in 400 l of transport buffer.
After preincubation with SB analogues, NBMPR, or Me2SO for 15 min,
uptake assays were started by adding an equal volume of transport
buffer containing 3H-labeled uridine (10 M) plus inhibitors or Me2SO.
Uptake assays were stopped by five rapid washes with ice-cold trans-
port buffer containing 1 mM unlabeled competing uridine. The cell
pellets were lysed in 10% SDS before quantification of radioactivity.
Equilibrium Binding of [3H]NBMPR by Intact Cells—Binding of
NBMPR to K562 cells was measured using an assay described in detail
previously (19). Briefly, total binding (5  105 cells/assay) was assessed
in the transport buffer described above to which had been added graded
concentrations (0.05–5 nM) of [3H]NBMPR. Alternatively, K562 cells
were first incubated with various concentrations of SB analogues, and
then 0.5 nM [3H]NBMPR was added. Binding was assessed at room
temperature for 45 min. Nonspecific binding was determined by addi-
tion of 10 M non-radioactive NBMPR in a set of replicate assay
mixtures.
Preparation of Membranes and Photoaffinity Labeling of Membranes
with [3H]NBMPR—Buffy coats from normal donors were obtained from
the American Red Cross (Charlotte, NC). The human erythrocytes were
isolated by density-gradient centrifugation (2600 rpm) using His-
topaque 1077 (Sigma). Human erythrocyte ghost membranes were pre-
pared as described earlier (20). [3H]NBMPR binding assays were per-
formed at room temperature in 10 mM Tris (pH 7.1) containing 0.01%
CHAPS (w/v). Incubations were initiated by adding an aliquot of 3 g of
erythrocyte ghost membranes to a glass tube containing the 0.5 nM
[3H]NBMPR in the absence or presence of various concentrations of
SB203580-iodo. Incubations were terminated after 45 min by dilution
with 5 ml of ice-cold 10 mM Tris (pH 7.1) followed by rapid filtration
through Whatman GF/B filters, which were then washed once with 5 ml
of ice-cold 10 mM Tris (pH 7.1). Nonspecific binding of [3H]NBMPR was
determined in the presence of 10 M NBMPR.
Analysis of Intracellular Nucleotides by High Performance Liquid
Chromatography—G9c cells (1  107), treated as described in the figure
legends, were harvested, and the samples were prepared and analyzed
for nucleotides as described previously (21).
RESULTS
SB203580 Prevents the Ara C-dependent Differentiation of
K562 Cells through Inhibition of Ara C Uptake—Incubation of
human K562 erythroleukemia cells with 50 nM Ara C increased
the benzidine-positive staining of these cells in a time-depend-
ent manner with 80% differentiation occurring after 96 h. To
determine whether p38 MAPK was involved in regulating the
differentiation of these cells, K562 cells were co-incubated with
Ara C and SB203580. Addition of 10 M SB203580 inhibited
greater than 90% of the Ara C-dependent differentiation of
these cells after 96 h (Fig. 1A). To further investigate the
influence of p38 MAPK inhibitors on this process, we examined
whether these compounds affected the uptake of Ara C into
cells. K562 cells were incubated with 50 nM [3H]Ara C and
increasing concentrations of SB203580 or SB203580-iodo, an
analogue of SB203580 with similar inhibitory effects on p38
MAPK (22). Surprisingly, both SB203580 and SB203580-iodo
significantly inhibited the uptake of [3H]Ara C into K562 cells
in a dose-dependent manner (Fig. 1B).
Inhibition of [3H]Uridine Uptake by p38 MAPK Inhibitors—
Because these results suggested that nucleoside transport was
affected by these compounds, we examined whether the uptake
of [3H]uridine was prevented by the p38 MAPK inhibitors.
Incubation of K562 cells with four different SB derivatives (Fig.
2A) demonstrated that SB203580-iodo, SB203580, and
SB202474 inhibited the uptake of [3H]uridine in a dose-de-
pendent manner, whereas SB220025 was without effect (Fig.
2B). SB202474 does not inhibit p38 MAPK, whereas SB220025
inhibits this kinase with a Ki similar to SB203580 (7, 14). Thus
these results demonstrated that the effects on [3H]uridine up-
take occurred independently of p38 MAPK inhibition. Analysis
of the data revealed an IC50 of 93.5  1.5 and 689.4  222.2 nM
for SB203580-iodo and SB203580, respectively (Fig. 2B). In
addition, the related compound SB202190 also inhibited
[3H]uridine uptake in a dose-dependent manner (data not
shown).
Effects of p38 MAPK Inhibitors on Equilibrative Binding of
[3H]NBMPR to Intact K562 Cells or Human Erythrocyte Mem-
branes—Since previous studies suggested that the majority of
nucleoside uptake in K562 cells occurred by NBMPR-sensitive,
equilibrative transporters (23), we investigated whether the
uptake of [3H]NBMPR was prevented by the p38 MAPK inhib-
itors. Addition of [3H]NBMPR to K562 cells demonstrated that
this compound was rapidly transported into K562 cells in a
time-dependent manner (data not shown). Incubation of K562
cells with SB203580-iodo potently inhibited the uptake of
[3H]NBMPR into these cells (Fig. 2C). Moreover, using isolated
human erythrocyte membranes, we found that SB203580-iodo
directly interfered with the binding of 3H-labeled NBMPR to
nucleoside transporter with an IC50 of 0.5 M (Fig. 2C).
FIG. 1. Effects of SB203580 on Ara C-induced erythroid differ-
entiation of K562 cells and [3H]Ara C uptake in K562 cells. A,
K562 cells were exposed to 50 nM Ara C in the presence or absence of
SB203580 at concentrations and times indicated. The percentages of
hemoglobin-containing cells that stained positive for benzidine were
obtained by counting at least 1000 cells/sample under microscopy using
100 magnification. Data represent the mean  S.D. of triplicate
samples of n  3 experiments. B, K562 cells were incubated with 50 nM
[3H]Ara C in the presence of 0.1–10 M of the p38 inhibitor SB203580,
SB203580-iodo, or Me2SO (DMSO) for 30 min. The effects of SB203580
and SB203580-iodo on [3H]Ara C uptake were determined as described
under “Materials and Methods,” and the data represent the assay of
duplicate samples.
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Inhibition of Salvage Pyrimidine Nucleotide Synthesis by
SB203580-iodo or NBMPR-mediated Inhibition of Nucleoside
Transport—Finally, the efficacy of the SB derivatives in pre-
venting the uptake and salvage of pyrimidine nucleosides was
further evaluated using a uridine-dependent cell model system
(G9c). The G9c cell line is a Chinese hamster ovary cell line
that lacks the capacity for de novo pyrimidine synthesis and
requires exogenous uridine to synthesize pyrimidine ribo- (or
deoxy-) nucleotides for cell growth (24). G9c cells were first
deprived of uridine for 24 h and then incubated with increasing
concentrations of SB203580-iodo, NBMPR, or Me2SO for an
additional 8 h in the presence or absence of 5 M uridine.
Removal of uridine from the growth medium resulted in the
depletion of the UTP and CTP pools, whereas the purines, ATP
and GTP, were unaffected (Fig. 3). Addition of 5 M uridine
to the growth medium restored the intracellular pyrimidine
nucleotide pools; however, addition of SB203580-iodo and
NBMPR prevented pool restoration in a dose-dependent man-
ner (Fig. 3). By contrast, coincubation of uridine-starved G9c
cells with SB203580-iodo or NBMPR alone for an additional 8 h
had no obvious effect on pyrimidine pools in comparison with
the uridine-starved G9c cells (data not shown). These results
indicated that inhibition of nucleoside transporters by the SB
analogues was sufficient to inhibit the salvage of pyrimidine
nucleosides in vivo.
DISCUSSION
The salvage of pyrimidine nucleosides is critically dependent
on facilitated transport into cells. In addition, cellular uptake
of chemotherapeutic nucleoside analogues such as Ara C or
gemcitabine (2,2-difluorodeoxycytidine) occurs by equilibra-
tive nucleoside transport (25–28). The results of the current
study demonstrate that the uptake of nucleosides and nucleo-
side analogues is potently inhibited by the imidazoline class of
p38 MAPK inhibitors. While our results do not eliminate a role
for p38 MAPK in Ara C-mediated differentiation of K562 cells,
these data show that the SB compounds inhibit nucleoside
transport independently of p38 MAPK activity. Specifically,
SB202474, an analogue of SB203580 that does not inhibit p38
MAPK (7), dose dependently inhibited nucleoside transport.
Consistent with this observation, incubation of K562 cells with
SB202474 also prevented the Ara C-dependent differentiation
of these cells in a dose- and time-dependent manner (72 h:
control, 4.4  0.8%; 10 M SB202474, 4.8  0.4%; 50 M
SB202474, 9.0  0.4%; 50 nM Ara C, 33.7  3.0%; 50 nM Ara C
plus 10 M SB202474, 20.1  2.1%; 50 nM Ara C plus 50 M
SB202474, 8.8  3.0%. 96 h: control, 8.2  1.6%; 10 M
SB202474, 9.1  2.0%; 50 M SB202474, 9.9  1.9%; 50 nM Ara
C, 72.9  6.9%; 50 nM Ara C plus 10 M SB202474, 50.8  6.6%;
50 nM Ara C plus 50 M SB202474, 9.4  1.5%). The observa-
tion that SB202474 was less effective than either SB203580 or
SB203580-iodo suggests that the absence of a fluorobenzyl ring
may reduce the efficiency of nucleoside transport inhibition
(see Fig. 2A). By contrast, SB220025, a novel inhibitor of p38
MAPK with similar potency (IC50  60 nM) (29) to SB203580
(IC50  48 nM) (7, 14), failed to inhibit nucleoside transport in
K562 cells. Thus these results show that some SB analogues
inhibit nucleoside transport in a p38 MAPK-independent man-
FIG. 2. Structures of SB class of p38 MAPK inhibitors and
effects on [3H]uridine and [3H]NBMPR uptake in K562 cells and
human erythrocyte membrane proteins. A, the chemical structures
of the four SB analogues used in this study are shown. B, the indicated
compounds were tested for their capacity to inhibit the uptake of 5 M
[3H]uridine in K562 cells. The IC50 of SB203580 and SB203580-iodo on
uridine uptake was determined by incubation with 5 M [3H]uridine in
the presence of 0.01–10 M SB203580, SB203580-iodo, or Me2SO con-
trol for 1 min. C, 3 g of human erythrocyte membrane proteins or 5 
105 K562 cells/sample were incubated in sodium-containing transport
buffer containing 0.5 nM [3H]NBMPR in the presence of 0.05–10 M
of SB203580-iodo. The effects of the SB compounds on binding of
[3H]NBMPR were determined as described under “Materials and Meth-
ods.” Data are shown as percentage of control binding where the “con-
trol” was the binding of 0.5 nM [3H]NBMPR in the absence of inhibitors.
Each point represents the mean  S.D. from n  2 experiments con-
ducted in duplicate.
FIG. 3. Effects of SB analogues and NBMPR on intracellular
ribonucleotide pools in uridine-starved G9c cells. G9c cells were
starved for uridine for 24 h and then incubated with SB203580-iodo
(SB-iodo), NBMPR, or Me2SO (DMSO) at the concentration indicated in
the absence or presence of 5 M uridine for an additional 8 h. Intracel-
lular UTP, CTP, GTP, and ATP were extracted and measured as de-
scribed under “Materials and Methods.” The levels of intracellular ATP,
GTP, CTP, and UTP of unstarved G9c cells are 29.8, 6.8, 5.3, and 18.7
nmol/1  107 G9c cells, respectively; the levels of intracellular ATP,
GTP, CTP, and UTP of starved G9c cells are 38.6, 10.7, 0.7, and 0.6
nmol/1  107 G9c cells, respectively. The data shown are plotted as the
percentage of the G9c starvation control and represent the mean of
duplicate samples. S, starvation; S-con, starvation control.
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ner and provide insight into the structure/activity relationship
of these compounds.
The results of our studies demonstrate that the equilibrative
transporters are targets for inhibition by this class of p38
MAPK inhibitors. In human erythroleukemia (K562) cells,
80–90% of total nucleoside transport activity occurs by equili-
brative, NBMPR-sensitive (es) transport, whereas the remain-
der occurs by an NBMPR-insensitive (ei) transport process
(23). Using K562 cells as a model system, we observed that
greater than 90% of the uridine transport was inhibited by the
SB compounds. Moreover using K562 cells or membranes from
erythrocytes we demonstrated a specific, competitive inhibition
of NBMPR binding, strongly indicating that the SB analogues
inhibited the activity of human ENT1.
The pattern of nucleoside transporter expression has been
shown to vary according to the cell line or origin (1). Our data
demonstrating that the SB analogues completely prevented the
salvage of pyrimidine nucleosides and that SB203580-iodo was
more effective than NBMPR at inhibiting uridine transport or
the repletion of intracellular pyrimidine nucleotide pools in G9c
cells suggests additional effects of these compounds on the ei or
concentrative transporters. Measuring uridine uptake in the
presence of NBMPR in these cells demonstrated that the SB
compounds inhibited both ei and es nucleoside transporters
(data not shown). Whether there are similar inhibitory effects
of these compounds on other types of nucleoside transporters
(i.e. concentrative) remains to be determined.
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